WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) (the “Company”) today announced that the Company intends to offer to sell, subject to market and other conditions, 4,945,000 shares of its common stock in an …
Out of that vast number, I think there are three especially promising cancer immunotherapies to watch in 2018 ... billion means that high expectations are baked into the stock price. That leaves Incyte. It's been a disappointing year …
Athena: My pick this week is the biotech company, Incyte Corporation (INCY). I know Holmes and RoadRunner have held this earlier. I also see this stock has been through quite a lot of ups and downs over the last six months. I made my …
INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM ... CO TO PAY SYROS $10 …
Incyte Corporation (Nasdaq:INCY), a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, will visit the Nasdaq MarketSite in Times Square. In honor of the …
Key biotech stocks, Amgen AMGN and Biogen BIIB reported second quarter results yesterday -- both companies surpassed earnings and sales estimates. There were several other key updates as well from companies like Incyte
Lilly and Incyte said they plan to launch a Phase 3 clinical program for atopic dermatitis later this year. Shares of Lilly were up 88 cents, or 1.1 percent, at $83.31 in late New York Stock Exchange trading on Thursday, while shares of …
NEW YORK, NY / ACCESSWIRE / May 19, 2017 / It has been an impressive month for Mercadolibre, especially after …